General trends in life sciences M&AAlthough the COVID-19 pandemic that defined 2020 continued to shape much of the life sciences industry in 2021, the way that it did was markedly different. Increased focus on digitization, with life sciences companies placing a premium on innovative and tech‑driven assets. [4]CVRs and earnouts remain popular mechanisms to bridge valueContingent value rights and earnouts also continued to be a popular approach in life sciences transactions in 2021. Pending further guidance from the FTC, significant uncertainty hangs over the life sciences M&A landscape. [6] 2021 SRS Acquiom Life Sciences M&A Study, SRS Acquiom, at p. 6 (Sept. 2021), available at https://www.srsacquiom.com/resources/life-sciences-deal-terms/ (noting that 218 of the 295 life sciences deals in the SRS Acquiom dataset – i.e., private‑target life sciences company transactions announced from 2008 to date – included an earnout).

Source: New York Times January 22, 2022 00:12 UTC